David Brister

MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.

Veryant, Inc. provides powerful COBOL and Java technology solutions to enable organizations to quickly and safely extend current applications to meet new business needs and demands. The private company is based in Westchester, IL. The company's portable, robust solutions translate into cost-effective, future-proof computing. Veryant's ISCOBOL Evolve enables organizations to retain current COBOL investments while simultaneously offering a path forward to take advantage of the openness, portability, and power of the Java platform without retraining staff or rewriting code.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Oxford Capital Partners LLP (Oxford Capital Partners) is a venture capital subsidiary of Oxford Capital Partners Holdings Ltd founded in 1999 by Tedd Mott and David Edward Christian Mott. The firm is headquartered in Oxford, the United Kingdom.

Biocleave Ltd. develops and sells microbial technology for the production of renewable chemicals and biofuels. It also provides biobutanol and other C4 chemical products. The firm also engages in microbiology and metabolic engineering through fermentation and commercial production scale. Its products include biobutanol chemicals and fuel, acetone, and butyric acid. The company was founded by Edward M. Green in 2003 and is headquartered in Abingdon, the United Kingdom.

Aitua Ltd. engages in the commercialization of intellectual properties of companies in the field of life sciences. It provides support to new bio-ventures by investing in the initial stage. The company was founded in June 2006 and is headquartered in Cambridge, the United Kingdom.

Crysalin Ltd. develops crysalin lattice technology for protein structure determination. Its portfolio includes crysalins, a protein-based nanotechnology for application in protein structure determination, as well as biosensor development and optoelectronics. The company was founded by Martin Noble and John Sinclair in June 2007 and is headquartered in Oxfordshire, the United Kingdom.